Telix Pharmaceuticals Q2 revenue at $204mln, up 63% YoY.

• Telix Pharmaceuticals reports Q2 2025 revenue of $204mln, up 63% YoY. • FY 2025 revenue guidance of $770mln to $800mln reaffirmed. • Gozellix launched in the US and commercial dose deliveries commenced. • Gozellix assigned a Level II HCPCS code, a prerequisite for transitional pass-through payment status. • ProstACT Global Phase 3 trial milestone achieved, with all 30 patients consented for Part 1.

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has reported a significant 63% year-over-year increase in revenue for Q2 2025, reaching approximately $204 million. This strong performance reaffirms the company's FY 2025 revenue guidance of $770 million to $800 million [1].

The quarter was marked by several key developments, including the U.S. launch of Gozellix®, which has been assigned a Level II HCPCS code, a crucial step towards transitional pass-through payment status [2]. Additionally, the company achieved a key milestone in its ProstACT™ Global Phase 3 trial, with all 30 patients consented for Part 1 [1].

The company's strategic initiatives and regulatory achievements are expected to enhance its industry positioning and stakeholder value. Despite emerging competitive pricing pressures, Telix has effective strategies in place to manage the impact on average selling price [1].

Analysts remain optimistic about Telix Pharmaceuticals' stock. The most recent analyst rating is a Buy with a A$31.00 price target [1].

References:
[1] https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-achieves-63-revenue-growth-in-q2-2025
[2] https://finance.yahoo.com/news/telix-reports-204m-revenue-63-080600921.html